Osteoporosis is a disease that is characterized by low bone mass, deterioration of bone tissue, and disruption of bone microarchitecture: it can lead to compromised bone strength and an increase in the risk of fractures (1).
bone remodeling (as measured by biochemical markers of bone resorption or formation) increases bone fragility and risk of fracture.
There are factors associated with an increased risk of osteoporosis-related fractures. These include general factors that relate to aging and sex steroid deficiency, as well as specific risk factors such as use of glucocorticoids (which cause decreased bone formation and bone loss), reduced bone quality, and disruption of microarchitectural integrity. Fractures result when weakened bone is overloaded, often by falls or certain daily chores (8) .
Classification
Osteoporosis can be classified into two main groups by considering the factors affecting 
Clinical Consequences
Clinical evaluation Osteoporosis has been mislabeled as a women's disease by the public, but it affects men, too: young men are afflicted by it, which usually goes undiagnosed until a fracture brings the patient to a doctor. However, delayed interventions are usually unsuccessful. The diagnosis of osteoporosis is never taken as primary osteoporosis without ruling out the secondary causes. A good history and physical examination of the patient always reveal certain clues about the presence of another disease: certain special laboratory evaluations might be needed to rule out other responsible diseases.
Clinical findings and complications
Fractures and their complications are the relevant clinical sequelae of osteoporosis. Osteoporosis is a silent disease until the patient experiences a fracture. A recent fracture at any major skeletal site, such as vertebrae (spine), proximal femur (hip), distal forearm (wrist), or shoulder in an adult older than 50 years with or without trauma, should suggest that the diagnosis of osteoporosis needs further urgent assessment involving diagnosis and treatment. Clinical risk factors are listed in (Table 2 ). The pathogenesis of osteoporosis-related fractures is summarized in ( Figure  2 ) (10, 11) .
Fractures may cause chronic pain, disability, and death. Hip fractures are associated with 15-20% increased mortality rate within 1 year, with a higher mortality rate in men than in women, followed by a 2.5-fold increased risk of future fractures. Approximately 20-50% hip fracture patients require long-term nursing homecare and suffer from decreased quality of life, social isolation, depression, and loss of self-esteem (12) . Fractures that occur spontaneously or following minor trauma (e.g., fall from a standing height or less)-called fragility fractures-are very common in osteoporotic individuals (13) .
Vertebral fractures might occur during daily chores without any trauma or fall, and they are the predictors of future fracture risk: the probability is fivefold for subsequent vertebral fractures and twofold to threefold for fractures at other sites (14, 15) .
The first complaint of the patient might be the loss of height caused by vertebral compression Environmental and medical factors increasing falls and measures that can be taken to prevent such falls at home are listed in (Table 3 ) (25) .
Prevention of falls
Falls are the cause of a majority of osteoporotic fractures; therefore, a program needs to be Table 1 Multifactorial interventions to prevent of falls in community-dwelling elderly people (Table 3 ). Older and frail persons and those who have had a stroke or are taking medications that decrease mental alertness are particularly predisposed toward falls. Although several interventions reduce the risk of falling, none of them apparently reduce the risk of fractures. Hip protectors do not reduce the risk of falling, but they reduce the risk of fracture. Patients at an older age with severe kyphosis, back discomfort, and gait instability could benefit from weight-bearing exercises, back strengthening, and balance training therapies.
Diagnosis of osteoporosis
Bone strength can be defined using BMD (70%) and bone quality (20%). It is easy to measure BMD, but, in clinical settings, bone quality is not measurable yet. The diagnosis of osteoporosis is established by the measurement of BMD or by the occurrence of a fragility fracture of the hip or vertebra or in the absence of major trauma (e.g., motor vehicle accident or fall from multiple stories). Laboratory testing revealed no secondary causes of osteoporosis (Table 1) .
Bone mineral density is measured by means of dual X-ray absorptiometry (DXA); it is the actual expression of the bone in absolute terms of grams of mineral (primarily, as g/cm 2 of calcium) per square centimeter of the scanned bone. BMD measurements of the hip and spine are used to establish or confirm the diagnosis of osteoporosis to predict future fracture risk and monitor patients. The difference between the patient's BMD and mean BMD of young females aged in the range of 20-29 years (divided by the standard deviation (SD) of the reference population) yields the T-score; comparing the BMD of a particular age, sex, and ethnicity-matched adult reference population is called the Z-score. As defined by the World Health Organization (WHO), osteoporosis is present when BMD is 2.5 SD or more below the average value for young healthy women (a T-score of <-2.5 SD). A second, higher threshold describes "low bone mass" or osteopenia as a T-score that lies between -1 and -2.5 SD. "Severe" or "established" osteoporosis denotes osteoporosis that has been defined in the presence of one or more documented fragility fractures (Table 4 ) (26).
Bone mineral density can be easily measured to detect bone density, but the degree of deterioration of the bone tissue cannot be measured in clinical settings, except for the biochemical markers of bone tissue (27) .
Fracture risk is closely correlated with bone strength and increases exponentially as the BMD decreases. Dual energy X-ray absorptiometry (DXA) measurements of hips are the best predictors of hip fracture risks. The measurements of the total hip, femoral neck, or total lumbar spine (or a combination of these sites) are the preferred measurement sites. If the hip and/or lumbar spine sites cannot be measured or become unusable (e.g., hyperparathyroidism or very obese patients), one-third (33%) of the site radius can be used. Other hip regions, including Ward's area and the greater trochanter, should not be used for diagnosis. BMD may be measured at either hip.
T-score criteria are applied for the BMD measured by means of central DXA at the femoral hip and lumbar spine for postmenopausal women and men aged 50 years and older. For premenopausal women, men less than 50 years of age, and children, the BMD diagnostic classification as defined by the WHO should not be applied. The International Society for Clinical Densitometry (ISCD) recommends using ethnic-or race-adjusted Z-scores: Z-scores of −2.0 or lower are defined as "low bone mineral density for chronological age" or "below the expected range for age" and those above −2.0 are defined as "within the expected range for age" (28) .
The United States Preventive Services Task Force (USPSTF) recommends the testing of all women aged 65 years and above and younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who exhibits no additional risk factors (29) . Indications for measuring BMD are listed at (Table 5 ) (13).
Fracture Risk Assessment Tool Model (FRAX)
The most important health consequence of osteoporosis is fractures. Recently, algorithms have been developed to predict the risk of fracture in individuals that incorporate significant predictors of fracture risk in addition to BMD. Estimating the 10-year risk of a major osteoporotic fracture (i.e., fracture of the hip, vertebra (clinical), forearm, or proximal humerus) is possible with algorithms that integrate the weight of clinical risk fractures for fracture risk with or without information on the BMD have been developed (www.shef.ac.uk/FRAX). They can be used to compute the 10-year probability of hip fracture or a major osteoporotic fracture (clinical spine, hip, forearm, or humerus).
Clinical risk factors used in FRAX are as follows (26) A vertebral fracture is consistent with the diagnosis of osteoporosis, even in the absence of a bone density diagnosis; it is an indication for pharmacologic treatment with osteoporosis Vertebral imaging (Vertebral fracture assessment) Asymptomatic vertebral fractures are very common in older patients necessitating vertebral imaging, which can be performed using a lateral thoracic and lumbar spine X-ray or lateral Vertebral Fracture Assessment (VFA) available on most DXA machines; this can be performed at the time of BMD assessment. Lateral spine imaging using conventional radiography or densitometric VFA is indicated when the T-score <-1.0 at the spine, total hip, femoral neck, and other sites is present (2) ( Table 6 ).
Biochemical bone turnover marker (BTM)
Bone remodeling (or turnover) occurs throughout life to repair fatigue damage and microfractures in the bone and to maintain mineral homeostasis. Biochemical markers of bone remodeling include resorption markers, namely serum C-terminal telopeptide type-I collagen (s-CTX) and urinary N-telopeptide (NTX), and formation markers, such as serum procollagen type-I N-terminal propeptide (s-PINP), which may provide information on fracture risk independent of BMD and predict the rapidity of bone loss in untreated patients. Therefore, the fracture risk prediction might get enhanced by their inclusion in assessment algorithms. Further, they can be used to predict the response to treatments. It was shown that there is a significant relationship between the reduction in BTMs following antiresorptive therapy and reduction in vertebral and non-vertebral fracture risk. In general, these studies showed that the greater the decrease in BTM, larger is the reduction in fracture risk.
International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group evaluated BTMs in the prediction of fracture risk and for monitoring treatment; it was recommended that bone formation markers (s-PINP) and bone resorption markers (s-CTX) should be used as reference markers and measured by standardized assays in observational and intervention studies (31) . Urinary-free cortisol level
Urinary histamine
Approach to a patient with osteoporosis A detailed history and physical examination together with BMD assessment, vertebral imaging to diagnose vertebral fractures (when appropriate), and the WHO-defined 10-year estimated fracture probability test are utilized to establish an individual patient's fracture risk (30) .
All postmenopausal women and men aged 50 years and above should be evaluated for osteoporosis risk in order to determine the need for BMD testing and/or vertebral imaging. In general, the more the risk factors, larger is the risk of fracture. Osteoporosis is preventable and treatable, but because there are no warning signs prior to a fracture, many people are not being diagnosed in time to receive effective therapy during the early phase of this disease. The factors that increase the risk of osteoporosis-related fractures are listed in (Table 2) .
Universal recommendations for all patients Several interventions, including an adequate intake of calcium and V-D, are fundamental aspects for any osteoporosis prevention or treatment program, including lifelong regular weight-bearing and muscle-strengthening exercises, cessation of tobacco use and excess alcohol intake, and treatment of risk factors for falling ( Table 2, 3) .
In order to maintain serum calcium at a constant level, an external supply of adequate calcium is necessary; otherwise, low serum calcium levels promote bone resorption to bring the calcium levels to normal. Calcium requirements increase among older persons; thus, the older population is particularly susceptible to calcium deficiency. The Institute of Medicine (IOM) recommends a daily intake of 1000 mg/ day for men aged 50-70 years and 1200 mg of calcium for women aged over 50 years and men aged over 70 years (33, 34) .
All calcium preparations are better absorbed when taken with food, particularly in the absence of the secretion of gastric acid. For optimal absorption, the amount of calcium should not exceed 500-600 mg per dose. Calcium carbonate is the least expensive and necessitates the use of the fewest number of tablets, but it may cause gastrointestinal (GI) complaints. Calcium citrate is more expensive, and a larger number of tablets are needed to achieve the desired dose; however, its absorption is not dependent on gastric acid and it does not cause GI complaints. Some food products contain excess oxalate, which prevents absorption of calcium by binding with it. Intakes in excess of 1200-1500 mg/ day may increase the risk of developing kidney stones, cardiovascular diseases, and strokes.
Vitamin D is necessary for calcium absorption, bone health, muscle performance, and balance. The IOM recommends a dose of 600 IU/ day until the age of 70 years in adults and 800 IU/day thereafter (34) (35) (36) . Many older patients are at a high risk for V-D deficiency, which include the following: patients with malabsorption issues (e.g., celiac disease) or other intestinal diseases (e.g., inflammatory bowel disease, gastric bypass surgery); gastric acidity; pernicious anemia; proton pump inhibitors; chronic renal or liver insufficiency; patients on medications that increase the breakdown of V-D (e.g., some anticonvulsive drugs); or glucocorticoids, which decrease calcium absorption; housebound and chronically ill patients; persons with limited sun exposure; individuals with very dark skin; and obese individuals. Alcohol: Excessive intake of alcohol has detrimental effects on bones, so it should be avoided.
The mechanisms are multifactorial and include predisposition to falls, calcium deficiency, and chronic liver disease, which, in turn, results in predisposition toward V-D deficiency. Persons predisposed toward osteoporosis should be advised against consuming more than 7 drinks/ week, 1 drink being equivalent to 120 mL of wine, 30 mL of liquor, or 260 mL of beer (23) .
Caffeine: Patients should be advised to limit their caffeine intake to less than 1 to 2 servings (8 to 12 ounces in each serving) of caffeinated drinks per day. Some studies showed that there is a relationship between caffeine consumption and fracture risk (37) .
Exercise: A regular weight-bearing exercise regimen (for example, walking 30-40 min per session) along with back and posture exercises for a few minutes on most days of the week should be advocated throughout life. Children and young adults who are active reach a higher peak bone mass than those who are not (38) .
Among older patients, these exercises help slow bone loss attributable to disuse, improve balance, and increase muscle strength, ultimately reducing the risk of falls (39) . Patients should avoid forward flexion, side-bending exercises, or lifting heavy objects because pushing, pulling, lifting, and bending activities compress the spine, leading to fractures.
Prevention of falls:
Falls are the precipitating cause for most osteoporotic fractures; some measures should be taken to prevent falls in the household, particularly for patients who are frail, taking some medications that affect mental alertness, thereby resulting in a stroke (40) ( Table 3 ).
Pharmacologic therapy
All osteoporotic patients should be evaluated for secondary causes of osteoporosis before starting treatment and subjected to BMD measurements using central DXA, including vertebral imaging studies when appropriate: the BTM levels should be obtained if monitoring of the treatment is planned.
Who should be considered for treatment? Postmenopausal women and men aged 50 years and above who present with the following should be considered for treatment: -A hip or vertebral fracture (clinically apparent or found on vertebral imaging) because it was shown that the patients with spine and hip fractures had reduced fracture risk with pharmacologic therapy, irrespective of the T score.
Determination of fractures when the T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine -Low bone mass (T-score between −1.0 and −2.5 at the femoral neck or lumbar spine) and -10-year probability of a hip fracture ≥3% or a 10-year probability of a major osteoporosis-related fracture ≥20%
The anti-fracture benefits of Food and Drug Administration (FDA)-approved drugs have mostly been studied in women with postmenopausal osteoporosis. There are limited fracture data for men and cases involving glucocorticoid-induced osteoporosis. All antiresorptive agents increase bone mass, but only alendronate, risedronate, zoledronic acid, and SR are shown to decrease both vertebral and hip fractures. However, the efficacy of the remaining is only for vertebral fractures. Nonetheless, hip fractures cause increased morbidity, mortality, and healthcare costs as compared to vertebral fractures. All of these antiresorptive therapies do not stimulate bone formation, except currently available anabolic agents (namely, PTH), which increase bone strength and bone formation. They are particularly helpful for those having severe or established osteoporosis. Unfortunately, the adherence to and persistence toward these techniques are poor toward all osteoporosis therapies, which decrease the success of treatment.
Antiresorptive agents
Bisphosphonates are the most widely used drugs for the treatment of osteoporosis. Risedronate is used in men and women for the prevention and treatment of osteoporosis and glucocorticoid-induced osteoporosis. A drug holiday of up to 1 year after 7 years of therapy has been suggested (42).
Ibandronate is another BP used for the prevention and treatment of postmenopausal osteoporosis, which has proven efficacy in reducing the risk of spinal fractures of postmenopausal women suffering from osteoporosis, but it is not proven in reducing non-vertebral or hip fractures except for higher-risk subgroup. Ibandronate has been studied in trials of up to 3 years and its efficacy and safety beyond 3 years is not known (43) .
Zoledronic acid is used for the prevention and treatment of postmenopausal osteoporosis and osteoporosis in men as well as glucocorticoid-induced osteoporosis. It is given once yearly, administered intravenously, as a 5-mg infusion over a minimum of 15 min (44).
Cautions to be taken, contraindications, and complications to BP therapy The absorption of oral BPs is less than 1% with any food, beverage other than plain water, or medications within 2 h after drug administration. Oral BPs should be used with caution: they should not be used in patients with active upper GI diseases, inability to remain upright for 30-60 min, anatomic or functional esophageal abnormalities that might delay the transit of the tablet (achalasia, stricture, etc.), V-D deficiency, hypocalcemia, and hypersensitivity to drug and kidney failure (should be used with caution when the glomerular filtration rate is below 30 ml/min for risedronate and ibandronate or below 35 mL/min for alendronate and zoledronate). Teriparatide (recombinant human PTH 1-34) is used in the treatment of postmenopausal osteoporosis with a high risk of fracture, those who have failed or are intolerant to previous osteoporosis therapies, and to increase bone mass in men with idiopathic or hypogonadal osteoporosis. Teriparatide is also approved for the treatment of men and women with glucocorticoid-induced osteoporosis. Serum calcium, PTH, and 25 (OH) D levels should be checked before treatment (50) . Teriparatide has a "black box" warning because of the occurrence of osteosarcomas in rats treated with very high doses of teriparatide; it is contraindicated in patients at increased risk of osteosarcoma (those with Paget's disease of the bone), having open epiphyses, history of irradiation involving the skeleton, unexplained elevation of alkaline phosphatase levels of skeletal origin, or patients with primary or any other form of secondary untreated or unresolved hyperparathyroidism.
The drugs decreasing the fracture risk in vertebral and non-vertebral sites are listed in (Table 8) .
Combination or sequential therapies
There is no evidence showing that a combination treatment with 2 or more osteoporosis drugs or sequential use of therapeutically agents shows any benefit on the natural history of osteoporosis or fracture risk reduction. In most patients, long-term treatment needs to be continued. The beneficial effects of treatment with drugs other than BPs wear off soon after the therapy is discontinued, but they may be maintained for longer periods of time after the cessation of BP therapy.
It is recommended that treatment review should be performed after 5 years for alendronate, risedronate, or ibandronate and after 3 years for zoledronic acid. Individuals with fracture risk should continue osteoporosis therapy without a drug holiday until we have convincing new data on the subject.
Conclusion
Osteoporosis is a common and silent disease until it is complicated by fractures that become common. It was estimated that 50% women and 20% of men over the age of 50 years will have an osteoporosis-related fracture in their remaining life. These fractures are responsible for lasting disability, impaired quality of life, and increased mortality, with enormous medical and heavy personnel burden on both the patient's and nation's economy. Osteoporosis can be diagnosed and prevented with effective treatments, before fractures occur. Therefore, the prevention, detection, and treatment of osteoporosis should be a mandate of primary healthcare providers. 
